Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CoV-RBD-scNP-001 + 3M-052-AF
- Development stage
- Unknown
- Lead developer
- Duke University
- Modality
- Nanoparticles → Drug Delivery Systems, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
CoV-RBD-scNP-001 + 3M-052-AF is a **combination vaccine candidate** targeting SARS-CoV-2 and related betacoronaviruses. The vaccine consists of a recombinant **receptor binding domain (RBD)** of the SARS-CoV-2 spike protein engineered onto a **ferritin-based nanoparticle scaffold** (scNP for sortase-conjugated nanoparticle), and is adjuvanted with **3M-052-AF**, a synthetic **Toll-like receptor 7/8 (TLR7/8) agonist** formulated in an aqueous solution. This combination is designed to induce strong and broad **neutralizing antibody responses** as well as T cell–mediated immunity. Studies in non-human primates and mice show that RBD-scNP + 3M-052-AF elicits high titers of cross-neutralizing antibodies against SARS-CoV-2, its major variants (including Beta, Delta, and Omicron), SARS-CoV-1, and related bat coronaviruses, and provides robust protection from both upper and lower respiratory tract infection. The 3M-052-AF adjuvant boosts the immunogenicity compared to formulations lacking this adjuvant[2][3][4][5][6][7][9].
- Other names
- RBD-scNP + 3M-052-AFRBD-scNP adjuvanted with 3M-052-AF
02
Targets
RBD (SARS-CoV-2 spike receptor-binding domain)TLR8 (Toll-like receptor 8)TLR7 (Toll-like receptor 7)
Beyond the preview
Go deeper on CoV-RBD-scNP-001 + 3M-052-AF.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CoV-RBD-scNP-001 + 3M-052-AF.